Furthermore, a hereditary deficiency of C5 or treatment with the US Food and Drug Administration–approved anti-C5 monoclonal antibody (eculizumab) often leads to severe, life-threatening fungal infections, highlighting the complement system’s essential role in tackling fungal pathogens (107, 108). This evidence concerns the gene C5 and fungal infectious disease.